Nine for 2021

Views & Analysis

Nine for 2021: Addressing the pandemic legacy

In this second 'Nine for 2021' article, IQVIA’s Sarah Rickwood looks at four issues which will directly impact pharma in 2021: t

Views & Analysis

Nine for 2021: The COVID-19 legacy

In the first of a two part series, IQVIA's Sarah Rickwood covers nine key trends and events that will affect the global healthcare and pharmaceutical industries in 2021.

News

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks